TYR

Tyro Payments Ltd-Tyro Welcomes RBA Update. Invitation to Market Briefing

时间：2025-07-15 11:38:35 市场： 综合

关联： TYR.AU

Tyra Biosciences Doses First Patient in Phase 2 Study of Tyra-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (Surf302)

时间：2025-06-30 20:00:14 市场： 美股 综合

关联： TYRA

aTyr Pharma Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $16

时间：2025-02-18 19:04:51 市场： 美股 综合

关联： ATYR

Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

时间：2025-01-30 05:05:15 市场： 美股 综合

关联： TYRA

aTyr Pharma Announces Third Positive Dsmb Review for Efzofitimod in Phase 3 Efzo-Fit™ Study in Pulmonary Sarcoidosis

时间：2024-12-10 21:01:52 市场： 美股 综合

关联： ATYR

Tyra Biosciences Inc : Qtrly Shr Loss $0.41

时间：2024-11-08 05:50:18 市场： 美股 综合

关联： TYRA

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for Tyra-300, an Investigational Oral Fgfr3-Selective Inhibitor, in Phase 1/2 Surf301 Study in Patients With Metastatic Urothelial Cancer (Muc)

时间：2024-10-25 06:21:42 市场： 综合 美股

关联： TYRA

Tyra Biosciences Inc : Bofa Global Research Raises to Buy From Neutral; Raises Price Objective to $31 From $22

时间：2024-10-18 21:34:58 市场： 美股 综合

关联： TYRA

Point72 Asset Management, L.p. Reports 6.2% Passive Stake in aTyr Pharma as of Oct 14 - SEC Filing

时间：2024-10-16 05:04:04 市场： 美股 综合

关联： ATYR

Tyra Biosciences Names Doug Warner Chief Medical Officer Tyra Biosciences (TYRA) said late Tuesday that it has appointed Doug Warner as its chief medical officer.The company said Warner held roles with increasing responsibility over 18 years at Amgen (AMGN).Most recently, Warner was chief medical officer for eFFECTOR Therapeutics.

时间：2024-09-11 04:47:25 市场： 美股 综合

关联： LENZ AMGN TYRA